Global /Australia /Healthcare /Drug Manufacturers - Specialty & Generic /NXS
chevron_leftBack
Next Science Ltd. logo

Next Science Ltd.

NXS
ASX: NXS Delayed
0.1450AUD 0%
0.1020 USD
As of 13 June 2026, Next Science Ltd. has a market cap of $29.82M USD, ranking #34285 globally and #913 in Australia. It ranks #3093 in the Healthcare sector, and #185 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
34285
Country Rank
913
Sector Rank
3093
Industry Rank
185
Key Stats
Market Cap
$29.82MUSD
42.43M AUD
Enterprise Value
$34.49MUSD
49.04M AUD
Revenue (TTM)
$23.66MUSD
33.66M AUD
EBITDA (TTM)
-$8.82MUSD
-12.53M AUD
Net Income (TTM)
-$10.11MUSD
-14.39M AUD
EBITDA Margin
-37%
Profit Margin
-43%
PS Ratio
1.3
PB Ratio
-49.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Harry Hall open_in_new
Founded
2012
Website
nextscience.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0% - 3.6% -3.3% 116% 21%

News

Loading...

Markets

Exchange Ticker Price
Australian Securities Exchange
MIC: XASX
PRIMARY
NXS
Next Science Ltd
ISIN: AU0000041329
Shares Out.:
292.625M1 Shares Float: 290.743M2
TV:
SA:
YF:
GF:
BA:
NXS
MS:
0.1450 AUD
OTC Markets
MIC: OTCM
NXSCF
Next Science Ltd
ISIN: AU0000041329
TV:
SA:
YF:
GF:
BA:
MS:
0.0850 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Next Science Ltd.

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Australia)
Name
Market Cap diff.
PE
$1.09B
1.55B AUD
4K%
52.7
$121.18M
172.39M AUD
306%
-
$112.65M
160.26M AUD
278%
18.1
$98.52M
140.17M AUD
230%
14.1
$55.57M
79.06M AUD
86%
-
BNIGF
$49.41M
66%
-
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$36.75B
108.92B ILS
123K%
24.2
$29.56B
99K%
-
$15.84B
107.34B CNY
53K%
16.0
CIPLA
$11.16B
1.06T INR
37K%
23.4
LUPIN
$11.04B
1.05T INR
37K%
22.7
$9.09B
61.6B CNY
30K%
80.6
chevron_leftBack